Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene

• Published in: Human genetics Vol. 107; no. 4; pp. 366 - 371
• Main Authors: SESTINI, Roberta, VIVARELLI, Rossella, BALESTRI, Paolo, AMMANNATI, Franco, MONTALI, Enrico, PAPI, Laura
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01-10-2000; Berlin; New York, NY
• Subjects: Adult; Biological and medical sciences; Child; Child, Preschool; DNA - genetics; DNA Mutational Analysis; Exons; Female; Genes, Neurofibromatosis 2; Haplotypes; Humans; Male; Medical sciences; Middle Aged; Mosaicism; Mutation; Neurofibromatosis 2 - genetics; Neurology; Pedigree; Phenotype; Polymorphism, Single-Stranded Conformational; Tumors of the nervous system. Phacomatoses; Human; Neurofibromatosis II; Nervous system diseases; Phacomatosis; Genetic marker; Chromosome; Genetic disease; Microsatellite DNA; Neurofibromatosis; Benign neoplasm; Mutation; Lymphocyte; Tumor suppressor gene; Polymorphism
• ISSN: 0340-6717; 1432-1203
• DOI: 10.1007/s004390000378

Neurofibromatosis type 2 (NF2) is an autosomal dominant cancer syndrome that predisposes to the development of bilateral vestibular schwannomas sometimes associated with schwannomas at other locations, meningiomas, ependymomas and juvenile posterior subcapsular lenticular opacities. This disease is caused by inactivating mutations in the NF2 tumour-suppressor gene, located in 22q12. Recently, somatic mosaicism has been demonstrated in some "de novo" NF2 patients. We here report the genetic study of 33 NF2 patients from 33 unrelated Italian families. Twelve mutations were characterised, including seven newly identified mutations and five recurrent ones. Furthermore, we describe one patient with an inactivating mutation that lies in exon 13 but that is present in only a portion of the lymphocytes and, more importantly, a clinically normal individual carrying a somatic/germinal mosaicism for a nonsense mutation in exon 10 of the NF2 gene. Our results confirm the relatively high percentage of mosaicism for mutations in the NF2 gene and establish the importance of evaluating genomic DNA from several tissues, in addition to lymphocytes, so as to identify mosaicism in "de novo" NF2 patients and their relatives. In addition, the demonstration of somatic and/or gonadal mosaicism is an important tool for accurate genetic counselling in families with sporadic cases of NF2.